Baseline patient characteristics and patient-reported outcomes organised for each cluster
| Baseline variables | Concordant to disease activity cluster (n=109) | Dominant fatigue cluster (n=13) | Dominant pain and fatigue cluster (n=18) |
|---|---|---|---|
| Women, n(%) | 76 (69.7) | 9 (69.2) | 10 (55.6) |
| Age (years) | |||
| mean±SD | 52.5±13.3 | 52.2±11.4 | 54.2±15.4 |
| median (Q1–Q3) | 54 (44–62) | 55 (51–60) | 47 (44–64) |
| DAS28CRP (0–9.4) | |||
| mean±SD | 4.5±1.2 | 4.3±1.0 | 4.5±0.9 |
| median (Q1–Q3) | 4.41 (3.7–5.4) | 4.10 (3.8–4.7) | 4.6 (3.7–5.0) |
| Pain (0–100) | |||
| mean±SD | 50.8±25.2 | 53.7±17.6 | 53.4±19.2 |
| median (Q1–Q3) | 50 (30–70) | 53 (46–60) | 60 (37–68) |
| Fatigue (0–100) | |||
| mean±SD | 40.4±24.6† | 53.6±23.8 | 49.9±16.1 |
| median (Q1–Q3) | 42 (20–57) | 52 (46–60) | 51 (41–75) |
| Physical functioning (0–3) | |||
| mean±SD | 0.9±0.7 | 0.7±0.4 | 0.8±0.6 |
| median (Q1–Q3) | 0.8 (0.4–1.3) | 0.6 (0.5–0.8) | 0.6 (0.4–0.9) |
| RA quality of life (0–30) | |||
| mean±SD | 9.1±6.8† | 8.0±4.5 | 10.6±7.7 |
| median (Q1–Q3) | 8 (4–13) | 9 (5–14) | 7 (5–10.3) |
| Sleep quality (0–21) | |||
| mean±SD | 7.9±4.3† | 8.3±3.5† | 8.2±3.6 |
| median (Q1–Q3) | 7 (5–11) | 7 (5–8) | 9 (5–11) |
| Symptom duration (weeks) | |||
| mean±SD | 30.3±30.4 | 29.4±37.7 | 34.7±27.1 |
| median (Q1–Q3) | 22 (13–36) | 38 (26–52) | 14 (13–19) |
| Comorbidities (present), n(%) | 72 (66.1) | 10 (76.9) | 16 (88.9) |
| IPQ-R treatment control* (5–25) | |||
| mean±SD | 19.1±2.2 | 17.9±2.1 | 18.5±2.2 |
| median (Q1-Q3) | 19 (18–21) | 18 (18–19) | 18 (18–19) |
*Patients’ belief in the effectiveness of treatment to control RA at treatment initiation.
†Missingness for patient-reported outcomes: 0.9% (pain; fatigue), 4.6% (RA quality of life), 7.7% (sleep quality, ‘dominant fatigue’ cluster), 10.1% (sleep quality, ‘concordant’ cluster).
comorbidities, number of patients having at least one comorbidity at trial screening; DAS28CRP, 28-joint disease activity score using C-reactive protein level; IPQ-R, Revised Illness Perception Questionnaire; Q1, quartile 1 (25th percentile); Q3, quartile 3 (75th percentile); RA, rheumatoid arthritis